Sonoma Pharmaceuticals (SNOA) 10-K2021 FY Annual report

Filed: 14 Jul 21, 5:25pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: accuracy, addendum, aerosol, airborne, Amazon, ancillary, antiseptic, Arai, ARTG, Article, backup, Barcelona, biocidal, biocompatible, biofarma, Biotech, blocked, breeding, Bruce, buyer, canal, car, cellular, chain, chemistry, closer, COBRA, Combo, committed, constituent, cough, counter, crusty, Dermodacyn, discomfort, divest, divested, Dvonch, Dyamed, ear, earliest, Egypt, eighteen, EMC, Endocyn, fewer, flatter, forge, France, GAAP, Gabriel, GECA, gentle, goal, ground, heath, highest, hypochlorite, Hypotonic, immune, inflamed, ingrown, innate, instant, interfering, Jerry, lender, lighter, lookback, lump, MannaPro, mode, moisturizing, mouth, Nasocyn, neck, necrotic, NOL, nose, Notwithstanding, Ocucyn, online, Oracyn, outer, overflow, owed, Pack, parent, path, PetSmart, Pharma, pharmacy, pink, primary, prime, prominent, proper, Quantifying, raw, ready, Receipt, red, reemphasize, resume, revision, root, rot, salt, Science, senescent, shelf, slightly, soothing, spearheaded, spreadsheet, stain, stringent, stuffy, sum, suspected, sync, Te, teeth, thin, Thornton, throat, thrush, toe, tolerate, Tractor, transitionary, uncovered, understated, University, user, Vero, veterinary, VetSynova

Removed: ACA, acting, added, affiliate, affordability, AmerisourceBergen, barrier, bear, Benchmark, bottom, buy, Cardinal, Ceramax, commence, consecutive, constantly, cream, CVS, Dawson, deciding, difficulty, dispensing, distraction, emotional, Exuvimax, facing, flat, fourth, goodwill, grocery, heavily, influence, influential, inside, invalidate, landscape, leave, Lipogrid, live, loyon, McKesson, Microdacyn, NAFTA, North, open, opposed, optimal, opting, paper, passed, placement, PPACA, pursuing, repeal, resell, responded, Sanfer, scaly, seasonal, slower, thereof, treating, type, USA, veterinarian, Walmart, withhold

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SNOA similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 23.1

Independent Registered Public Accounting Firm’s Consent

We consent to the incorporation by reference in the Registration Statement of Sonoma Pharmaceuticals, Inc. on Form S-3 (File No. 333-221477), Form S-8 (File No. 333-228898), Form S-8 (File No. 333-219058), Form S-8 (File No. 333-214760), Form S-8 (File No. 333-205171), Form S-8 (File No. 333-171412), Form S-8 (File No. 333-182263), Form S-8 (File No. 333-195530), Form S-8 (File No. 333-194314), Form S-8 (File No. 333-163988) and Form S-3 (File No. 333-250925) of our report, which includes an explanatory paragraph as to the Company’s ability to continue as a going concern, dated July 14, 2021, with respect to our audits of the consolidated financial statements of Sonoma Pharmaceuticals, Inc. and Subsidiaries as of March 31, 2021 and 2020 and for the two years in the period ended March 31, 2021, which report is included in this Annual Report on Form 10-K of Sonoma Pharmaceuticals, Inc. for the year ended March 31, 2021.

/s/ Marcum llp

Marcum llp

New York, NY

July 14, 2021